3 High Insider Ownership Growth Stocks On The ASX To Watch

As the Australian sharemarket faces a softer start to the week, with ASX 200 futures indicating a slight decline, investors are keenly observing how global rate hikes and local economic signals will influence market dynamics. In this environment, growth companies with high insider ownership can be particularly appealing as they often demonstrate strong internal confidence and alignment of interests between management and shareholders.

Top 10 Growth Companies With High Insider Ownership In Australia

Name	Insider Ownership	Earnings Growth
Wisr (ASX:WZR)	10.3%	94.2%
Starpharma Holdings (ASX:SPL)	19.3%	92%
SKS Technologies Group (ASX:SKS)	19.3%	27.7%
PDI Gold (ASX:PDI)	10.4%	63.6%
Forrestania Resources (ASX:FRS)	24.7%	72.9%
Emerald Resources (ASX:EMR)	18.3%	23%
DXN (ASX:DXN)	13.5%	129.3%
Austral Resources Australia (ASX:AR1)	23.5%	28.2%
Adveritas (ASX:AV1)	17.6%	99.9%
Advanced Engineered Materials (ASX:AEM)	35.1%	58.7%

Click here to see the full list of 114 stocks from our Fast Growing ASX Companies With High Insider Ownership screener.

Here we highlight a subset of our preferred stocks from the screener.

FDC Consolidated Holdings (ASX:FDC)

Simply Wall St Growth Rating: ★★★★★☆

Overview: FDC Consolidated Holdings Limited operates in Australia, offering construction, fitout, and refurbishment services with a market cap of A$1.26 billion.

Operations: The company generates revenue from its construction segment with A$1.02 billion and its fitout & refurbishment segment with A$672.32 million.

Insider Ownership: 12.2%

FDC Consolidated Holdings shows potential as a growth company with high insider ownership, despite recent financial setbacks. The company reported a net loss of A$58.2 million for the fiscal year ending June 2026, contrasting with the previous year's profit. However, revenue increased to A$1.69 billion from A$1.5 billion and is expected to reach A$1.9 billion in 2027, outpacing Australian market growth rates. Analysts forecast significant earnings growth and high future return on equity, suggesting long-term potential despite current challenges.

• Unlock comprehensive insights into our analysis of FDC Consolidated Holdings stock in this growth report.
• According our valuation report, there's an indication that FDC Consolidated Holdings' share price might be on the cheaper side.

Regis Healthcare (ASX:REG)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Regis Healthcare Limited provides aged care services in Australia and has a market cap of A$1.44 billion.

Operations: The company's revenue is primarily derived from its Residential Aged Care and Home Care and Retirement Living Services, totaling A$1.35 billion.

Insider Ownership: 38.7%

Regis Healthcare is poised for growth with substantial insider buying and a focus on strategic acquisitions. The company's earnings, forecasted to grow at 13.1% annually, are expected to outpace the broader Australian market. Despite a dividend not fully covered by earnings, Regis trades significantly below estimated fair value, suggesting potential upside. Recent leadership changes and an active M&A pipeline targeting high-quality operators further align with its growth objectives in the healthcare sector.

• Click here and access our complete growth analysis report to understand the dynamics of Regis Healthcare.
• Our comprehensive valuation report raises the possibility that Regis Healthcare is priced lower than what may be justified by its financials.

Starpharma Holdings (ASX:SPL)

Simply Wall St Growth Rating: ★★★★★★

Overview: Starpharma Holdings Limited is a biopharmaceutical company focused on the research, development, and commercialization of dendrimer technology for pharmaceutical and healthcare applications both in Australia and internationally, with a market cap of A$379.09 million.

Operations: The company generates revenue of A$12.67 million from the discovery, development, and commercialization of dendrimers for various applications.

Insider Ownership: 19.3%

Starpharma Holdings demonstrates strong growth potential with substantial insider buying and no significant insider selling over the past three months. Recently added to the S&P/ASX All Ordinaries and Emerging Companies Indexes, Starpharma reported a significant increase in sales to A$12.05 million for FY2026, although it still recorded a net loss of A$7.47 million. The company completed a follow-on equity offering raising approximately A$31.99 million, supporting its forecasted revenue growth of 43.5% annually, well above market averages.

• Get an in-depth perspective on Starpharma Holdings' performance by reading our analyst estimates report here.
• Our comprehensive valuation report raises the possibility that Starpharma Holdings is priced higher than what may be justified by its financials.

Taking Advantage

• Embark on your investment journey to our 114 Fast Growing ASX Companies With High Insider Ownership selection here.
• Want To Explore Some Alternatives? The end of cancer? These 35 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com